Capricor Therapeutics Q4 2023 GAAP EPS $(0.020) Beats $(0.200) Estimate, Sales $12.088M Beat $10.600M Estimate
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) reported Q4 2023 GAAP EPS of $(0.020), surpassing the $(0.200) estimate, with sales of $12.088M exceeding the $10.600M forecast. This represents a significant increase over the previous year's sales of $959.903K.
February 29, 2024 | 9:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics reported a significant beat on both EPS and sales estimates for Q4 2023, with a remarkable year-over-year sales growth.
Beating both EPS and sales estimates significantly, especially with such a substantial year-over-year sales increase, is likely to instill investor confidence and could lead to a positive short-term price movement for CAPR. The magnitude of the beat and growth rates are critical factors in this analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100